Bedaquiline is a novel drug designed to treat drug-resistant tuberculosis. Extensive clinical trials have shown it is effective against drug-resistant TB by inhibiting the ATP synthase enzyme in TB bacteria. Bedaquiline offers higher treatment success rates and shorter treatment durations than traditional antibiotics, but also has some potential side effects. It is recommended for use in combination with other antibiotics as part of a comprehensive treatment plan for drug-resistant TB.